Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 1,928 shares of Nektar Therapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $31.37, for a total transaction of $60,481.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Jillian B. Thomsen also recently made the following trade(s):
- On Tuesday, February 19th, Jillian B. Thomsen sold 1,808 shares of Nektar Therapeutics stock. The shares were sold at an average price of $42.39, for a total transaction of $76,641.12.
NKTR stock opened at $32.02 on Friday. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $92.17. The stock has a market cap of $5.58 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 14.83 and a current ratio of 14.94.
Several hedge funds have recently added to or reduced their stakes in NKTR. Meeder Asset Management Inc. raised its position in shares of Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new stake in shares of Nektar Therapeutics during the 1st quarter worth about $27,000. CSat Investment Advisory L.P. raised its position in shares of Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth about $39,000. Finally, Sandy Spring Bank bought a new stake in shares of Nektar Therapeutics during the 4th quarter worth about $59,000. Institutional investors own 94.90% of the company’s stock.
NKTR has been the topic of several recent research reports. Mizuho reiterated a “buy” rating and issued a $81.00 price objective on shares of Nektar Therapeutics in a research report on Wednesday, January 23rd. ValuEngine downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 31st. HC Wainwright reiterated a “hold” rating and issued a $47.00 price objective on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. BMO Capital Markets initiated coverage on shares of Nektar Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $75.00 price objective on the stock. Finally, TheStreet upgraded shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a research report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $69.73.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: Cash Asset Ratio
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.